Zealand Pharma Reports Positive Trial Data for Obesity/Diabetes Drug and Regulatory Opinion for Short Bowel Syndrome Treatment

Zealand Pharma released positive Phase 2 ZUPREME-2 trial results for petrelintide, showing up to 9.2% weight loss and significant HbA1c reductions in individuals with overweight or obesity and type 2 diabetes. Additionally, the company received a positive CHMP opinion for Zeydovio (glepaglutide) for short bowel syndrome. These developments highlight progress in addressing metabolic disorders and rare gastrointestinal conditions, potentially expanding treatment options for patients.